logo
Sign in

RGDXQ Stock Price, Chart, Stats & News

Response Genetics Inc
Save

Response Genetics Inc (RGDXQ) does not currently pay a dividend.

3,873
Market cap
–
Current P/E
–
Forward P/E

RGDXQ chart

About

Health care
Sector
Medical - Diagnostics & Research
Industry

Response Genetics, Inc., a life sciences company founded in Los Angeles, California, in 1999 (originally Bio Type, Inc., before its rebranding in August 2000), focuses on creating, advancing, and commercializing pharmacogenomic tests. These diagnostic tools are crucial for informing cancer treatment decisions by assessing specific indicators within tumor tissue samples that predict a patient's response to therapy. The company provides an extensive array of testing services, primarily through its ResponseDX suite, covering various cancers such as non-small cell lung, colorectal, gastric, gastroesophageal, melanoma, thyroid, breast, and glioma, in addition to a Tissue of Origin test.

Similar securities

Based on sector and market capitalization

Report issue